• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>NCI

NCI

NCI Inc Class A NCIT

Last Price$11.75Day Change (%)0.77%
Open Price$11.72Day Change ($)0.09
Day Range11.66–11.7952-Week Range5.87–13.12

As of Tue 11/25/2014 04:00 PM EST | USD

  1. NCI Awarded $12 Million Alliant Task Order

    NCI Awarded $12 Million Alliant Task Order

  2. BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th ...

    BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC- NCI -AACR Annual Symposium

  3. ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium

    ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium

  4. Exosome Diagnostics Demonstrates Superior Mutation Detection Utilizing Combined Exosomal RNA (exoRNA) and Cell-Free DNA (cfDNA) Isolation and Analysis

    Exosome Diagnostics Demonstrates Superior Mutation Detection Utilizing Combined Exosomal RNA (exoRNA) and Cell-Free DNA (cfDNA) Isolation and Analysis

  5. NDRI Elects Three New Directors to Board

    NDRI Elects Three New Directors to Board

  6. Phase 1 Dose Escalation Data for Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity in B-Cell Non-Hodgkin Lymphomas and Malignant Rhabdoid Tumor

    Phase 1 Dose Escalation Data for Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity in B-Cell Non-Hodgkin Lymphomas and Malignant Rhabdoid Tumor

  7. Foundation Medicine’s Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis ...

    Foundation Medicine’s Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology’s PARP inhibitor, Rucaparib

  8. Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients

    Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients

  9. Tokai Pharmaceuticals Presents Updated Interim Galeterone ARMOR2 Data Showing Activity in Patients with Castration-Resistant Prostate Cancer (CRPC) Including Those Showing a Variant Form of Prostate ...

    Tokai Pharmaceuticals Presents Updated Interim Galeterone ARMOR2 Data Showing Activity in Patients with Castration-Resistant Prostate Cancer (CRPC) Including Those Showing a Variant Form of Prostate Cancer Resistant to Hormone Therapy

  10. Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer ...

    Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.